These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 14703956)

  • 1. Treating type 2 diabetes in renal insufficiency: the role of pioglitazone.
    Fritsche L; Budde K; Glander P; Einecke G; Diekmann F; Schötschel R; Neumayer HH
    Int J Clin Pharmacol Ther; 2003 Oct; 41(10):488-91. PubMed ID: 14703956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single- and multiple-dose pharmacokinetics of pioglitazone in adolescents with type 2 diabetes.
    Christensen ML; Meibohm B; Capparelli EV; Velasquez-Mieyer P; Burghen GA; Tamborlane WV
    J Clin Pharmacol; 2005 Oct; 45(10):1137-44. PubMed ID: 16172178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Extended Minimal Physiologically Based Pharmacokinetic Model: Evaluation of Type II Diabetes Mellitus and Diabetic Nephropathy on Human IgG Pharmacokinetics in Rats.
    Chadha GS; Morris ME
    AAPS J; 2015 Nov; 17(6):1464-74. PubMed ID: 26276217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics of pioglitazone in patients with impaired renal function.
    Budde K; Neumayer HH; Fritsche L; Sulowicz W; Stompôr T; Eckland D
    Br J Clin Pharmacol; 2003 Apr; 55(4):368-74. PubMed ID: 12680885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and clinical efficacy of pioglitazone.
    Hanefeld M
    Int J Clin Pract Suppl; 2001 Sep; (121):19-25. PubMed ID: 11594240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone: side effect and safety profile.
    Shah P; Mudaliar S
    Expert Opin Drug Saf; 2010 Mar; 9(2):347-54. PubMed ID: 20175701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.
    Teranishi T; Ohara T; Maeda K; Zenibayashi M; Kouyama K; Hirota Y; Kawamitsu H; Fujii M; Sugimura K; Kasuga M
    Metabolism; 2007 Oct; 56(10):1418-24. PubMed ID: 17884455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.
    Ko GJ; Kang YS; Han SY; Lee MH; Song HK; Han KH; Kim HK; Han JY; Cha DR
    Nephrol Dial Transplant; 2008 Sep; 23(9):2750-60. PubMed ID: 18388116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats.
    Yoshimoto T; Naruse M; Nishikawa M; Naruse K; Tanabe A; Seki T; Imaki T; Demura R; Aikawa E; Demura H
    Am J Physiol; 1997 Jun; 272(6 Pt 1):E989-96. PubMed ID: 9227442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New oral hypoglycemic drugs in diabetic kidney disease].
    Dylewska M; Graczyk M
    Wiad Lek; 2017; 70(6 pt 2):1193-1196. PubMed ID: 29533912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
    Defronzo RA; Mehta RJ; Schnure JJ
    Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatotoxicity with thiazolidinediones: is it a class effect?
    Scheen AJ
    Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pioglitazone.
    Al-Majed A; Bakheit AH; Abdel Aziz HA; Alharbi H; Al-Jenoobi FI
    Profiles Drug Subst Excip Relat Methodol; 2016; 41():379-438. PubMed ID: 26940171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency.
    Harrower AD
    Clin Pharmacokinet; 1996 Aug; 31(2):111-9. PubMed ID: 8853933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.
    Bailey CJ; Green BD; Flatt PR
    Expert Opin Investig Drugs; 2010 Aug; 19(8):1017-25. PubMed ID: 20629618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antidiabetic agents and renal insufficiency].
    Robles NR; Blanco J
    Nefrologia; 2002; 22(4):325-8. PubMed ID: 12369123
    [No Abstract]   [Full Text] [Related]  

  • 18. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Glucose lowering drugs in case of impaired renal function].
    Assink MA; Abrahams AC; Rookmaaker MB
    Ned Tijdschr Geneeskd; 2014; 158():A6907. PubMed ID: 24618238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pioglitazone/glimepiride (Duetact) for diabetes.
    Med Lett Drugs Ther; 2007 Jan; 49(1253):9-11. PubMed ID: 17261966
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.